Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SHP674 in Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
2022-002190-28Phase 2
- Sponsor
- Servier
- Start
- Jul 2022
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pegaspargase in acute lymphoblastic leukemia (ALL), sponsored by Servier.
02
Drugs
pegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2022-002190-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002190-28.